Precision Motion Health

Executive Summary

Precision Motion Health (PMH) has developed a Soft Tissue Intelligence Platform that integrates sensor-based diagnostics, biomechanics, and AI analytics to objectively assess, predict, and personalize treatment for musculoskeletal (MSK) and soft tissue injuries. Targeting the workers' compensation, occupational health, and enterprise wellness markets, PMH addresses the critical need for objective outcome measurement in MSK care, moving beyond subjective patient-reported outcomes. By providing data-driven insights, the platform aims to reduce disability duration, lower claim costs, and improve return-to-work outcomes. Founded in 2018 and based in San Francisco, PMH operates in the diagnostics sector, leveraging advancements in wearable sensors and machine learning. While the company has not disclosed total funding or valuation, its focus on the high-cost MSK market positions it for potential growth, particularly as employers and insurers seek technology to manage chronic pain and injury recovery. The platform's ability to integrate with existing workflows and provide real-time biomechanical analysis could differentiate it in a fragmented market, though validation through clinical studies and commercial traction remains critical.

Upcoming Catalysts (preview)

• Q3 2026Key Partnership with Major Workers' Compensation Insurer60% success
• Q1 2027FDA 510(k) Clearance for Diagnostic Software50% success
• Q4 2026Series A Funding Round Announcement55% success